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Agranulocytosis is a serious, although rare, adverse reaction to sulfasalazine, which is used to treat inflammatory joint and
bowel disease. We performed a genome-wide association study comprising 9,380,034 polymorphisms and 180 HLA
alleles in 36 cases of sulfasalazine-induced agranulocytosis and 5,170 population controls. Sulfasalazine-induced agranulo-
cytosis was significantly associated with the HLA region on chromosome 6. The top hit (rs9266634) was located close to
HLA-B, odds ratio (OR) 5.36 (95% confidence interval (CI) (2.97, 9.69) P52.553 1028). We HLA-sequenced a second
cohort consisting of 40 cases and 142 treated controls, and confirmed significant associations with HLA-B*08:01,
OR52.25 (95% CI (1.02, 4.97) P50.0439), in particular the HLA-B*08:01 haplotype HLA-DQB1*02:01-DRB1*03:01-
B*08:01-C*07:01, OR53.79 (95% CI (1.63, 8.80) P50.0019), and with HLA-A*31:01, OR54.81 (95% CI (1.52, 15.26)
P50.0077). The number needed to test for HLA-B*08:01 and HLA-A*31:01 to avoid one case was estimated to be 1,500.
We suggest that intensifiedmonitoring or alternative treatment should be considered for known carriers ofHLA-B*08:01 or
HLA-A*31:01.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 Agranulocytosis is a serious, although rare, adverse reaction to
sulfasalazine-a drug used to treat inﬂammatory joint and bowel dis-
ease. The risk is most pronounced during the ﬁrst 3 months of
treatment, and agranulocytosis should be suspected in patients with
unexplained fever or nonspeciﬁc illness during this period. There
are no good predictors for sulfasalazine-induced agranulocytosis.
WHAT QUESTION DID THIS STUDY ADDRESS?
 The aim was to identify genetic variants predisposing to
sulfasalazine-induced agranulocytosis in a European population.
WHAT DOES THIS STUDY ADD TO OUR
KNOWLEDGE?
We performed a genome-wide association study (GWAS)
and identiﬁed genetic variants in the HLA region that
increased the risk of sulfasalazine-induced agranulocytosis
signiﬁcantly.
HOW THIS MIGHT CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 We suggest that known carriers of HLA-B*08:01 or HLA-
A*31:01 should be placed under intensiﬁed monitoring when
starting sulfasalazine or be offered an alternative drug.
Agranulocytosis is a blood dyscrasia characterized by an absolute
neutrophil count below 0.5 3 109/L (500/lL).1 The vast major-
ity of cases are drug-related, either through direct dose-dependent
cytotoxicity or idiosyncratic reactions to at least 125
nonchemotherapy drugs.2–4 Idiosyncratic agranulocytosis leads to
a rapid decline in neutrophils that causes a high risk of over-
whelming infection, with an average mortality rate of about
5%.5–7 The onset of drug-induced idiosyncratic agranulocytosis is
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usually within months of starting therapy, and the reaction is
generally believed to be immune-mediated.4 In the few instances
where genetic studies have been performed, associations with
human leukocyte antigen (HLA) genes or other genes associated
with the immune response have been found.4 This provides fur-
ther evidence for an immune-mediated mechanism for drug-
induced idiosyncratic agranulocytosis.
Sulfasalazine (Salazopyrin, Pﬁzer, Groton, CT), a drug devel-
oped in the 1930s for the treatment of inﬂammatory joint and
bowel disease, was reported to cause fatal idiosyncratic agranulo-
cytosis already in 1942.8 In nonfatal cases, patients usually
recover within weeks of drug withdrawal.7 The incidence was
estimated to be 1 in 2,400 patients during the ﬁrst month of
treatment, 1 in 700 during the second and third months
(0.14%), and 1 in 11,200 after more than 3 months of treatment
in a Swedish population.9 In the same population, the back-
ground incidence of agranulocytosis was approximately 1 in
150,000 inhabitants.9
Sulfasalazine-induced agranulocytosis is believed to be a host
immune response to a reactive metabolite of sulfasalazine.4 Sulfa-
salazine is ﬁrst split into 5-amino salicylic acid and sulfapyridine
by intestinal bacteria.10 Sulfapyridine is in contrast to 5-amino
salicylic acid rapidly absorbed into the bloodstream. It is further
metabolized in the liver into N-acetyl-sulfapyridine by the
enzyme N-acetyltransferase 2 (NAT2).11,12 N-acetyl-
sulfapyridine is primarily bioactivated by the enzyme CYP2C9
into a cytotoxic hydroxylamine that is subsequently excreted as a
glucuronic acid conjugate.13 Inherited variants of the drug-
metabolizing enzymes NAT2 or CYP2C9 could in theory shunt
the metabolism towards more toxic metabolites.14 It has been
speculated that slow NAT2 acetylators treated with sulfonamides
may be predisposed to idiosyncratic toxicity, such as severe skin
reactions and systemic lupus erythematosus.15–18 In a previous
study, we investigated whether coding variants in the NAT2 gene
inﬂuenced the risk of sulfasalazine-induced agranulocytosis.19 A
higher proportion of slow acetylators was seen among 39 cases of
sulfasalazine-induced agranulocytosis (69%) compared with 75
sulfasalazine-tolerant patients (45%). However, no difference in
slow acetylator frequency was seen between the 39 cases and 448
population-based control subjects. We further genotyped these
cases and treated controls for CYP2C9*2 and *3, but no associa-
tion between agranulocytosis and genotype was seen (unpub-
lished results). A subsequent study investigated the possible
association between sulfasalazine-induced agranulocytosis and
mutations in the human neutrophil elastase gene (ELANE) that
causes severe congenital neutropenia (SCN).20 None of the
mutations previously reported to cause SCN were found in 36
patients with agranulocytosis induced by sulfasalazine. No other
studies on candidate genes for sulfasalazine-induced agranulocy-
tosis have to our knowledge been published. The European
Drug-induced Agranulocytosis Consortium (EuDAC, see
Acknowledgments) was initiated with the aim to perform a
genome-wide association study (GWAS) to identify novel genetic
variants predisposing to agranulocytosis. We here present the
results on sulfasalazine-induced agranulocytosis.
RESULTS
Characteristics of 36 cases of agranulocytosis induced by sulfasala-
zine and 5,170 population controls collected in Sweden, Ger-
many, France, and Spain are shown in Supplementary Table S1.
Comparisons of demographic and clinical factors between the 30
cases recruited in Sweden and their 183 matched controls are
shown in Table 1.
Genome-wide association analyses
Sulfasalazine-induced agranulocytosis was associated with the
major histocompatibility complex (MHC) region (HLA region)
on chromosome 6 on a genome-wide level after adjusting accord-
ing to sex and genetic principal components 1–4, P < 5 3 1028
(Figure 1, Supplementary Figure S1). The single nucleotide
polymorphism (SNP) with the best evidence for association was
rs9266634, which is located in an intergenic region 22,000 bases
from HLA-B, odds ratio (OR) 5.36 (95% conﬁdence interval
(CI) 2.97, 9.69) P5 2.55 3 1028, (Table 2, Supplementary
Table S2, Supplementary Figure S1). There was also a signiﬁ-
cant association with the intergenic insertion rs202233001 posi-
tioned in a repeat region close to the paired box 1 gene (PAX1)
on chromosome 20, OR5 6.76 (95% CI 3.41, 13.38), P5 4.19
3 1028. When the data were adjusted for the top hit rs9266634,
the chromosome 20 SNP rs202233001 was no longer signiﬁ-
cantly associated.
Follow-up analyses were performed adjusting for each top hit
in a sequential manner (Table 2). After adjusting for rs9266634
on chromosome 6, rs111876221 on chromosome 5 reached
genome-wide signiﬁcance. This SNP is located in intron 1 of the
serine incorporator 5 gene (SERINC5). After adjusting for the
two independently associated rs9266634 and rs111876221, the
SNP rs113887891 on chromosome 1 was signiﬁcant on a
genome-wide level. This intron variant is in a repeat region in
the gene for the nonprotein-coding transcript LINC01762. After
adjusting also for rs113887891, the SNP rs12082628 on chromo-
some 1 was signiﬁcant on a genome-wide level. This variant is in
a repeat region in an intron of the cholinergic receptor, musca-
rinic 3 gene (CHRM3). All associated variants outside the HLA-
region were infrequent, and none of them had strong evidence of
being functional in primary B cells from peripheral blood.21 After
adjusting for rs9266634, rs111876221, rs113887891, and
rs12082628, no genome-wide signiﬁcant association remained.
Analysis of classical HLA alleles at second field resolution
The HLA alleles HLA-C*14:02 and HLA-B*08:01 were associ-
ated with sulfasalazine-induced agranulocytosis on an HLA-wide
level (P < 2.8 3 1024), OR5 7.72 (95% CI (2.90, 20.58)
P5 4.36 3 1025) and 2.92 (95% CI (1.71, 4.98) P5 8.37 3
1025), respectively (Table 2, Supplementary Table S3). The
top genome-wide SNP rs9266634 was in linkage disequilibrium
(LD) with both HLA-C*14:02 (D05 0.87, r25 0.01, P < 2.22
3 10216) and HLA-B*08:01 (D05 0.99, r25 0.16, P < 2.22 3
10216). A multiple analysis, including all associated HLA alleles
and the top SNP, shows that rs9266634 had a small independent
effect (Supplementary Figure S2). Top HLA types obtained by
sequential adjustment for each signiﬁcantly associated type are
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shown in Table 2. The association with HLA-B*08:01 was
strengthened after adjusting for HLA-C*14:02, OR5 3.24 (95%
CI (1.988 5.57) P5 2.26 3 1025). HLA-A*31:01 consistently
had odds ratios around 4, but P-values were above the deﬁned
HLA-wide signiﬁcance level.
We corrected for possible confounding by indication and pop-
ulation stratiﬁcation by considering the Swedish cohort sepa-
rately (Table 1). The odds ratio for HLA-C*14:02 was 11.08
(95% CI (4.10, 29.89) P5 2.05 3 1026) when Swedish cases
and population controls were compared, and 10.30 (95% CI
(2.44, 43.52) P5 1.51 3 1023) when Swedish cases were com-
pared with controls matched for diagnosis of inﬂammatory dis-
ease (Figure 2). The odds ratio for HLA-B*08:01 was 3.15 (95%
CI (1.78, 5.57) P5 7.83 3 1025) compared with population
controls, and 5.43 (95% CI (2.40, 12.27) P5 4.823 1025) com-
pared with matched controls. The corresponding odds ratios for
HLA-A*31:01 were 3.70 (95% CI (1.54, 8.90) P5 3.39 3
1023), and 4.97 (95% CI (1.54, 16.01) P5 7.25 3 1023)
(Figure 2).
Replication of SNPs and HLA alleles
An independent cohort recruited in Sweden was used for replica-
tion of the association with HLA (Table 3). We sequenced
HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, and HLA-
DPB1 in 40 cases of sulfasalazine-induced agranulocytosis and
142 controls treated with sulfasalazine for at least 90 days. Due
to correction for multiple testing of the ﬁve top HLA types
shown in Table 2, the cutoff for signiﬁcance was P < 0.01.
HLA-B*08:01 was nominally associated with agranulocytosis,
OR5 2.25 (95% CI (1.02, 4.97) P5 0.0439, C-statistic5 0.57)
(Table 4). Thirteen cases (32.5%) were heterozygous for HLA-
B*08:01, as compared to 25 controls (17.6%), and none were
homozygous. We hypothesized that these patients carried the
most frequent HLA-B*08:01 haplotype, HLA-DQB1*02:01-
Table 1 Characteristics of cases and matched controls recruited in Sweden for the discovery cohort
Cases (n5 30) Matched controls (n5 183) P
Gender, male [%] 14 [46.7] 80 [43.7] 0.92
Age, years at agranulocytosis [%] at diagnosis [%]
<25 1 [3.3] 6 [3.3] 0.49
25-29 2 [6.7] 10 [5.5]
30-34 2 [6.7] 4 [2.2]
35-39 2 [6.7] 7 [3.8]
40-44 1 [3.3] 12 [6.6]
45-49 1 [3.3] 15 [8.2]
50-54 5 [16.7] 14 [7.7]
55-59 7 [23.3] 43 [23.5]
60-64 5 [16.7] 25 [13.7]
65-69 2 [6.7] 27 [14.8]
70-74 0 14 [7.7]
>74 2 [6.7] 6 [3.3]
Diagnosisa [% of cases] [% of controls]
Rheumatoid arthritis 14 [46.7] 75 [41.0] 0.56
Crohn’s disease 3 [10.0] 41 [22.4] 0.15
Ulcerative colitis 3 [10.0] 48 [26.2] 0.06
Psoriasis arthritis 5 [16.7] 13 [7.1] 0.15
Ankylosing spondylitis 1 [3.3] 5 [2.7] 1.00
Arthritis unspecified 5 [16.7] 8 [4.4] 0.02
Sj€ogren’s syndrome 1 [3.3] 12 [6.6] 0.70
Total number of diagnosis 32 202
Cases included one of Swedish–Italian, one of Swedish–Finnish, and one of Finnish origin. Matched controls all had a diagnosis that is an indication for sulfasalazine
treatment.
aTwo cases had two diagnosis: rheumatoid arthritis and psoriasis arthritis, and Crohn’s disease and unspecified arthritis. Among the controls, 17 had two diagnosis and
one had three diagnosis. Tests used: chi2 test for comparisons of age, otherwise Fisher’s exact test.
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DRB1*03:01-B*08:01-C*07:01, which is present in 7.4% of
Europeans.22 Notably, all 13 cases with HLA-B*08:01 carried
HLA-C*07:01, DQB1*02:01, and DRB1*03:01, and thus proba-
bly had the common haplotype. In comparison, only 16 of 25
sulfasalazine-treated controls with HLA-B*08:01 carried this
combination of HLA alleles. The odds ratio for carrying HLA-
DQB1*02:01-DRB1*03:01-B*08:01-C*07:01 was 3.79 (95% CI
(1.63, 8.80) P5 0.0019, C-statistic5 0.61), which was statisti-
cally signiﬁcant (Table 4). Furthermore, the association with
HLA-A*31:01 was statistically signiﬁcant, OR5 4.81 (95% CI
(1.52, 15.26) P5 0.0077, C-statistic5 0.57) (Table 4). The
allele frequency of HLA-A*31:01 was high among cases (9%)
compared with the expected frequency 2.7% in Europeans.22
HLA-C*14:02 was only present in one control, and therefore too
rare to be assessed.
Predictive ability and clinical implications
The speciﬁcity to predict risk of agranulocytosis increased from
82.4% to 88.7% when using HLA-DQB1*02:01-DRB1*03:01-
B*08:01-C*07:01 instead of HLA-B*08:01. This indicates that
fewer patients would be falsely predicted as being at risk when
using the full haplotype. The sensitivity was 32.5% with either
HLA-B*08:01 or the full haplotype, but when combining HLA-
B*08:01 with HLA-A*31:01, the sensitivity increased to 47.5%.
With a sensitivity of 47.5% and an incidence of 0.0014 (1 in 700
patients receiving treatment),9 we could theoretically reduce the
incidence of agranulocytosis to 0.000735 (0.0014–0.475*0.0014)
by screening for HLA-B*08:01 and HLA-A*31:01. The number
needed to genotype (NNG) for HLA-B*08:01 and HLA-
A*31:01 to avoid one case was estimated to be about 1,500,
which is the reciprocal of the absolute risk reduction, 1/
(0.0014*0.475).
DISCUSSION
The sulphonamide sulfasalazine is known to carry a high risk of
agranulocytosis,8 and the relative risk is estimated to be almost 10
times higher than for the sulphonamide sulfamethoxazole.23 The
characteristics of our cases (53% women, median age 55–59 years,
median treatment time to onset 50 days) were similar to those
found in a previous study on the epidemiology of sulfasalazine-
induced agranulocytosis in Sweden.9 In the present study,
sulfasalazine-induced agranulocytosis was mainly associated with
the MHC region on chromosome 6 that encodes HLA genes.
Agranulocytosis induced by other drugs has previously been asso-
ciated with HLA.4,24–26 We found an association between
sulfasalazine-induced agranulocytosis and HLA-B*08:01 that was
replicated with similar ORs (2.92 vs. 2.25). All HLA sequenced
cases carrying HLA-B*08:01 also carried DQB1*02:01,
DRB1*03:01, and HLA-C*07:01, and the full haplotype con-
ferred a higher OR (3.79). This indicates that the HLA-
Figure 1 Manhattan plot of the genome-wide association analysis. Analysis of 36 cases induced by sulfasalazine vs. all controls with 9,380,034 SNPs
after imputation, adjusted by sex and genetic principal components 1–4. The red line shows the threshold for genome-wide significance of 5 3 1028. The
top SNP was rs9266634 marked in green is located in an intergenic region close to HLA-B on chromosome 6. There was also a significant association
with an intergenic insertion/deletion on chromosome 20, rs202233001, marked in green. The closest protein coding gene to this variant is the transcrip-
tion factor gene Paired Box 1 (PAX1). After adjustment for rs9266634, the intronic SNP rs111876221 in the gene serine incorporator 5 (SERINC5) on
chromosome 5, reached genome-wide significance. After adjustment for both rs9266634 and rs111876221, rs113887891 in a nonprotein coding RNA
gene (LINC01762) on chromosome 1 was significant on a genome-wide level. After adjusting also for this SNP, the intron variant rs12082628 in the gene
cholinergic receptor, muscarinic 3 (CHRM3) on chromosome 1 gave a significant result. SNP5 single nucleotide polymorphism, HLA5 human leukocyte
antigen, RNA5 ribonucleic acid.
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DQB1*02:01-DRB1*03:01-B*08:01-C*07:01 haplotype could be
a better predictor of agranulocytosis than HLA-B*08:01. How-
ever, the sensitivity did not change when adding the full haplo-
type, while it was higher when combining HLA-B*08:01 with
HLA-A*31:01.
Notably, HLA-B*08:01 and HLA-A*31:01 have both been
shown to increase the risk of carbamazepine hypersensitivity.27,28
In a European study on carbamazepine, individuals homozygous
for HLA-B*08:01 were more likely to suffer severe hypersensitiv-
ity than those carrying at least one copy of the common HLA-
B*07:02 allele.22,27 Several studies have shown that HLA-
A*31:01 increases the risk of carbamazepine hypersensitivity.28
There is no apparent chemical structural similarity between sulfa-
salazine and carbamazepine. We did not replicate our association
with the rare HLA-C*14:02 allele in the HLA sequenced cohort.
HLA-C*14:02 has an expected allele frequency of only 1.3% in
Europeans, but is more common in Asia, with allele frequencies
up to 8.2%.22 HLA-C*14:02 has previously been associated with
serious skin reactions due to phenytoin in patients of Thai
ancestry.29
There are three main proposed hypotheses through which
HLA can interact with a drug to trigger an inappropriate
immune response.28 According to the ﬁrst model, the drug binds
covalently to a peptide fragment that is presented on the MHC
Table 2 Top genome-wide associations and HLA associations with agranulocytosis induced by sulfasalazine in the discovery cohort
Associations CHR SNP BP
Alleles
(major/
minor) N
MAF
case
MAF
‘control OR [95% CI] P
Nearby
gene
a. Genome-wide
Adjusted by sex and 6 rs9266634 31346978 A/T 5,183 0.81 0.44 5.37 [2.97, 9.69] 2.5531028 HLA-B
genetic PC 1-4 20 rs202233001 21735353 C/CACA 5,081 0.14 0.03 6.76 [3.41, 13.38] 4.1931028 PAX1
Adjusted by sex, genetic
PC 1-4 and rs9266634
5 rs111876221 79535200 A/G 5,152 0.10 0.02 12.65 [5.15, 31.1] 3.2231028 SERINC5
Adjusted by sex, genetic
PC 1-4, rs9266634
and rs111876221
1 rs113887891 117006870 G/T 5,041 0.13 0.02 9.52 [4.24, 21.37] 4.7831028 LINC01762
Adjusted by sex, genetic
PC 1-4, rs9266634,
rs111876221 and
rs113887891
1 rs12082628 239797706 A/G 4,872 0.09 0.01 14.99 [5.75, 39.04] 3.0031028 CHRM3
b. HLA
6 HLA-C*14:02 31346171 A/P 5,206 0.07 0.01 7.72 [2.90, 20.58] 4.3631025
Adjusted by sex and 6 HLA-B*08:01 31431272 A/P 5,206 0.26 0.11 2.92 [1.71, 4.99] 8.3731025
PC 1-4 6 HLA-C*02:06 31346171 A/P 5,206 0.01 0.00 92.68 [8.02, 1071] 2.8631024
6 HLA-B*08:01 31431272 A/P 5,206 0.26 0.11 3.24 [1.88-5.57] 2.2631025
Adjusted by sex, PC 1-4 6 HLA-C*07:01 31346171 A/P 5,206 0.29 0.14 2.72 [1.62, 4.57] 1.4931024
and HLA-C*14:02 6 HLA-A*31:01 30019970 A/P 5,206 0.10 0.03 3.72 [1.63, 8.47] 1.7431023
Adjusted by sex, PC 1-4, 6 HLA-C*02:02 31346171 A/P 5,206 0.15 0.06 3.52 [1.81, 6.84] 2.0931024
HLA-C*14:02 6 HLA-A*31:01 30019970 A/P 5,206 0.10 0.03 4.24 [1.83, 9.82] 7.5731024
and B*08:01 6 HLA-C*07:02 31346171 A/P 5,206 0.25 0.15 2.67 [1.50, 4.77] 8.5131024
Adjusted by sex, PC 1-4, 6 HLA-B*07:02 31431272 A/P 5,206 0.24 0.15 3.57 [1.90, 6.72] 7.7431025
HLA-C*14:02, B*08:01 6 HLA-C*07:02 31346171 A/P 5,206 0.25 0.15 3.16 [1.74, 5.75] 1.6731024
and C*02:02 6 HLA-A*31:01 30019970 A/P 5,206 0.10 0.03 3.87 [1.64, 9.12] 1.9931023
Adjusted by sex, PC 1-4, 6 HLA-A*3101 30019970 A/P 5,206 0.10 0.03 4.42 [1.83, 10.68] 9.4831024
HLA-C*14:02, B*08:01, 6 HLA-B*5101 31431272 A/P 5,206 0.14 0.05 3.18 [1.25, 8.11] 1.5531022
C*02:02 and B*07:02 6 HLA-B*5501 31431272 A/P 5,206 0.03 0.01 5.48 [1.23, 24.31] 2.5331022
a. Top GWAS results based on 9,380,034 SNPs after imputation in 36 patients with sulfasalazine-induced agranulocytosis vs. all 5,170 controls. All results were adjusted
for sex and four genetic principal components (PC). No genome-wide significant signals were left after adjusting for four SNP variants. b. Odds ratios for the top HLA alleles
for patients with sulfasalazine-induced agranulocytosis. The effect was modeled per increase of one present HLA allele. Chromosomal location is according to the Genome
Reference Consortium human assembly GRCh37. Complete lists of associated SNPs and HLA types are available in the appendix.
GWAS5 genome-wide association study, CHR5 chromosome, PC5 genetic principal components, SNP5 single nucleotide polymorphism, BP5 base pair, N5 number,
MAF5minor allele frequency, OR [95% CI]5 odds ratio with 95% confidence interval. When referring to HLA allele: A5 absent, P5 present.
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molecule, while the second model proposes that the drug binds
directly to the T-cell receptor or MHC molecule. In the third
model, the drug binds noncovalently to the antigen-binding cleft
of the HLA protein, which alters the repertoire of peptides it can
bind.28 This last model has been demonstrated for abacavir, a
drug strongly associated with acute hypersensitivity syndrome
among carriers of the HLA-B*57:01 allele.30 It is not known
whether any of the proposed mechanisms explain agranulocytosis
induced by sulfasalazine. There is evidence that another sulpho-
namide, sulfamethoxazole, triggers an immune response by bind-
ing both covalently to proteins including MHC, and
noncovalently to MHC/peptide complexes.31
Although we found associations between sulfasalazine-induced
agranulocytosis and classical HLA alleles, we cannot exclude
inﬂuence from nearby noncoding regulatory variants. In the
HLA-region, it is generally difﬁcult to identify an actual causative
variant due to a high degree of gene density and polymorphism,
and extended linkage disequilibrium.32,33 Apart from our top hit
close to HLA-B, a genome-wide signiﬁcant association was
observed in an intergenic region on chromosome 20 close to
PAX1, a member of the paired box family of transcription fac-
tors. This infrequent variant is located in a repeat region and has
no evidence of being functional in primary B cells from periph-
eral blood.21 After correcting for the top HLA hit, we found an
association with a rare intronic variant in SERINC5, which enco-
des a protein that restricts human immunodeﬁciency virus (HIV)
infectivity.34 Based on imputed data from the Roadmap Epige-
nome project, the SERINC5 SNP is located in a weak enhancer
region in primary B cells from peripheral blood characterized by
histone 3 being monomethylated at lysine 4 (H3K4me1) and
acetylated at lysine 27 (H3K27ac).21 Lastly, after sequentially
adjusting for the other top hits, two infrequent SNPs on chromo-
some 1 were independently associated on a genome-wide level.
However, these associations were likely to be spurious since both
SNPs are in repeat regions and have no evidence of being regula-
tory variants in B-cells.21
There are several limitations of this study. First, sulfasalazine-
induced agranulocytosis is a rare event, and it is difﬁcult to iden-
tify a large enough number of cases. For the present study, cases
were collected over a period of 20 years, which resulted in a total
of 76 cases. Second, HLA sequencing could not be performed in
the discovery phase since we did not have access to DNA from
the controls. In the replication phase all cases and controls were
HLA-sequenced, thus making the results more reliable. Third,
several polymorphisms in the HLA loci are known to confer
genetic susceptibility to inﬂammatory arthritis or bowel disease.32
Due to the small sample size we did not stratify by disease; how-
ever, the distribution of diseases was similar among cases and
matched controls. We therefore believe that there was no con-
founding by indication. Fourth, the most frequent disease in our
cohort, rheumatoid arthritis, is strongly associated with a sub-
group of HLA-DRB1*04 alleles, and to a lesser extent seronega-
tive rheumatoid arthritis is associated with HLA-B*08.35 We did
not discriminate between seropositive and seronegative rheuma-
toid arthritis, and could not test whether serotype inﬂuenced the
detected association with HLA-B*08:01. Fifth, the number
needed to screen (NNG) for HLA-B*08:01 and HLA-A*31:01
to avoid one case was high, 1,500. HLA-A*31:01 also increases
Figure 2 Forest plot of associations with HLA in the discovery cohort. Estimated odds ratio (OR) with 95% confidence intervals (CI), P-value and C-
statistic for the independently associated HLA types HLA-C*14:02, HLA-B*08:01, HLA-C*02:02, HLA-B*07:02, and HLA-A*31:01 in 1) all discovery cases
and controls, 2) Swedish discovery cases and controls, and 3) Swedish discovery cases with matched controls. Matched controls were individuals who
had been treated with sulfasalazine and/or had been diagnosed with inflammatory joint or bowel disease. The effect is adjusted for sex and genetic princi-
pal components 1–4. HLA5 human leukocyte antigen.
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Table 3 Characteristics of the patients in the replication cohort collected in Sweden
Cases (n5 40) Controls treated90 days (n5 142) P
Gender, male [%] 18 [45.0] 64 [45.1] 1.00
Age, years at agranulocytosis [%] at enrolment [%]
<25 4 [10.3] 8 [5.6] 0.21
25-29 0 7 [4.9]
30-34 1 [2.6] 14 [9.9]
35-39 2 [5.1] 11 [7.7]
40-44 2 [5.1] 14 [9.9]
45-49 6 [15.4] 16 [11.3]
50-54 4 [10.3] 20 [14.1]
55-59 2 [5.1] 14 [9.9]
60-64 4 [10.3] 11 [7.7]
65-69 5 [12.8] 7 [4.9]
70-74 6 [15.4] 8 [5.6]
>74 3 [7.7] 12 [8.5]
Diagnosisa [% of cases] [% of controls]
Rheumatoid arthritis 20 [50.0] 71 [50.0] 1.00
Crohn’s disease 1[2.5] 3 [2.1] 1.00
Colitis, ulcerative or unspecified 10 [25.0] 5 [3.5] 1.253 1024
Psoriasis arthritis 2 [5.0] 18 [12.7] 0.25
Ankylosing spondylitis 0 24 [16.9] 0.07
Arthritis unspecified 6 [15.0] 22 [15.5] 1.00
Plantar fasciitis 1 [2.5] 0 0.22
Total number of diagnosis 40 143
Mean time to onset in days [range] 43 [16-90] —
Mean lowest neutrophil count x109cells/l [range] 0.03 [0-0.5] —
Mean daily dose in mgb [range] 2062 [500-4000] 1963 [500-3000] 0.40
Cases with co-suspected drugs [%] 0 —
Controls were patients treated with sulfasalazine for at least 90 days without reacting with agranulocytosis.
aOne control had two diagnosis: ulcerative colitis and arthritis. bDose missing for four controls. Tests used: chi2 test for comparisons of age, t-test for mean daily dose, oth-
erwise Fisher’s exact test.
Table 4 Replication of HLA types associated with sulfasalazine-induced agranulocytosis
HLA allele N N Case N Control MAF Case MAF Control OR 95% CI C Stat P
C*14:02 182 40 142 0.00 0.00 N/A
B*08:01 182 40 142 0.16 0.09 2.25 [1.02, 4.97] 0.574 0.0439
Full haplotype 182 40 142 0.16 0.06 3.79 [1.63, 8.80 0.606 0.0019
C*02:02 182 40 142 0.09 0.09 0.99 [0.39, 2.50] 0.501 0.9876
B*07:02 182 40 142 0.19 0.12 1.67 [0.84, 3.28] 0.571 0.1406
A*31:01 182 40 142 0.09 0.02 4.81 [1.52, 15.26] 0.566 0.0077
The HLA types were selected by sequential adjustment for each significant association in the discovery cohort. Associated HLA types were compared between replication
cases and controls treated 90 days or more using logistic regression. The effect was modeled per increase of one present HLA type. The full haplotype is HLA-
DQB1*02:01-DRB1*03:01-B*08:01-C*07:01.
N5 number, OR5 odds ratio, 95% CI595% confidence interval, C Stat5C statistic, N/A5 not available.
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the risk of carbamazepine-induced hypersensitivity or skin reac-
tion.28 Since HLA-A*31:01 is prevalent throughout the world,
and the reactions are common, only 15–43 patients starting car-
bamazepine need to be screened for HLA-A*31:01 to avoid one
case. There are other examples where preemptive genotyping is
recommended despite a high NNG, although this is unusual.28,36
HLA-B*15:02 is a strong predictor of the serious skin reactions
Stevens–Johnson’s syndrome and toxic epidermal necrolysis in
East Asia, where this HLA type is prevalent.28 Before starting car-
bamazepine, patients originating from East Asia should be tested
for HLA-B*15:02. Even in Asia, 10,000–24,665 patients need to
be screened to avoid one case, due to the rarity of these serious
skin reactions.
Strengths of this study are that it has a fairly large and homoge-
nous discovery cohort, and that the ﬁnding was replicated in a
second cohort. In general, pharmacogenomic associations are
robust and more likely to be translated into clinical practice than
genetic associations with complex traits.37 There are several rea-
sons. First, genetic variants associated with drug-related pheno-
types usually have larger effect sizes than those associated with
complex disease risk. Second, pharmacogenomic variants tend to
have higher allele frequencies than variants associated with com-
plex traits. This is possibly due to the fact that complex traits
have been subject to negative selection over the course of human
evolution, while pharmacogenomic variants only are deleterious
in the presence of a certain drug, and drug treatment is a rela-
tively new intervention. Third, pharmacogenomic variants are
more likely to be actionable, since it is easier to select an alterna-
tive drug than to modify risk factors for complex disease, such as
lifestyle. Fourth, it has been predicted that before long patients
will have their pharmacogenome readily available in their medical
records, thus removing the necessity to order the test.38
In conclusion, we have conﬁrmed that sulfasalazine-induced
agranulocytosis is associated with HLA-B*08:01 and HLA-
A*31:01 in Europeans. The association was stronger for the
HLA-DQB1*02:01-DRB1*03:01-B*08:01-C*07:01 haplotype
than for HLA-B*08:01 alone, but the NNG did not change
when using the full haplotype. Whether to use genetics in transla-
tional medicine to adapt drug treatment depends on the severity
of the expected adverse drug reaction (ADR) and the existence of
other treatment options.36 We believe that the drug sulfasalazine
fulﬁls these criteria, although the high NNG makes testing chal-
lenging. The solution could be to include HLA-B*08:01 and
HLA-A*31:01 into preemptive screening programs, where multi-
ple tests are performed at a low cost. Known carriers of HLA-
B*08:01 or HLA-A*31:01 starting sulfasalazine could then be
placed under intensiﬁed monitoring or be offered an alternative
drug. This individualization would be a further step towards per-
sonalized treatment of inﬂammatory disease.
METHODS
Ethical statement
The study was approved by the local Ethics Committees (2008/213 and
2010/231, Uppsala, Sweden; Dec. 22, 2014, Malaga, Spain; RTF011,
Barcelona, Spain; Charite-Universit€atsmedizin Berlin, Germany; CPP
Sud-Ouest et Outre-Mer I No. 1-09-24, Toulouse, France; and for
recruitment of Swedish controls Stockholm Dnr 2007-644-31 and
2011/463-32). Research was carried out in accordance with the latest
update of the Declaration of Helsinki. Written informed consent was
obtained from all participants. The study protocol has been indexed in
the European Network of Centres for Pharmacoepidemiology and Phar-
macovigilance (ENCePP) register at www.encepp.eu (“The EuDAC
Study”). Part of the replication cohort that had previously been collected
for genetic studies of sulfasalazine-induced adverse reactions was
approved by the Ethics Committee of the Medical Faculty, Uppsala Uni-
versity, Sweden (95-200 and 97-312).
Sample description
EuDAC consists of a network of investigators in Sweden, Spain, France,
and Germany. The basis for case recruitment in Sweden (www.swede-
gene.se) and France was through nationwide spontaneous ADR reports
sent from healthcare professionals to the respective national drug regula-
tory authority. In Spain, cases were recruited both from spontaneous
ADR reports and through active surveillance at 17 hospitals in Barce-
lona. German cases were recruited through active surveillance at 50 hos-
pitals in Berlin, as described.2
Each included subject was at least 18 years of age and able to give
informed consent. We deﬁned cases as patients who had developed an
absolute neutrophil count of 0.5 3 109/L or less (500/lL) during
drug therapy or within 7 days of stopping medication. Each case was
required to exhibit complete recovery after cessation of the drug with an
absolute neutrophil count >1.0 3 109/L (>1000/lL) or a compatible
bone marrow aspirate or biopsy. Additional inclusion and exclusion cri-
teria have been described previously.39 We collected clinical data (demo-
graphics, medical history, drug treatment history, laboratory data, and
ancestry) through interviews using a standardized questionnaire, and by
obtaining and reviewing medical records. At each center, cases were eval-
uated by at least one senior investigator, and a ﬁnal adjudication of the
complete dataset was performed by a specialist in hematology. Causality
assessment was according to the WHO standard algorithm.40
Overall, 243 cases were collected for the study. Seven Swedish cases
and two Spanish cases were excluded after adjudication due to either
exposure to chemotherapy, negative rechallenge, unknown white blood
cell count, diagnosis of chronic lymphatic leukemia, or missing clinical
data. No German or French case was excluded. Out of the 234 cases of
drug-induced agranulocytosis fulﬁlling all requirements, 36 were associ-
ated with sulfasalazine, which is the focus of this study. These cases origi-
nated from Sweden (n5 30), Germany (n5 3), and France (n5 3),
while Spain had no case induced by sulfasalazine (Supplementary Table
S1).
Consenting population controls were available from Sweden, Spain,
and Germany. In total, 5,170 controls were utilized: 4,891 unrelated
individuals from the Swedish Twin Registry,41 183 Spanish, and 96 Ger-
man individuals.2 Of the 183 Spanish controls, 147 had been recruited
in a previous study of upper gastrointestinal bleeding,42 while the
remaining 36 were healthy control subjects. Controls with a known his-
tory of agranulocytosis or neutropenia from any cause were excluded.
Matching of controls from the Swedish Twin Registry was performed by
linking with individual data from the Swedish National Patient Register,
and the Swedish Prescribed Drug Register. Matched controls were those
with a hospital diagnosis that is an indication for sulfasalazine treatment
(data available from 1964). Diseases included were Crohn’s disease,
ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis
arthritis, unspeciﬁed arthritis, and Sj€ogren’s syndrome. Some of these
controls had also collected prescriptions of sulfasalazine (data available
from July 2005). Patient characteristics were compared between discov-
ery cases and controls using Fisher’s exact and chi2 tests (Table 1).
For the replication, we used 40 cases of sulfasalazine-induced agranu-
locytosis and 142 controls who had been treated with sulfasalazine for a
minimum of 3 months (90 days) without developing agranulocytosis
(Table 3). Twenty-nine of the cases and all the controls had been col-
lected previously in Sweden for genetic studies of sulfasalazine-induced
adverse reactions.19,20 In addition, 11 new cases of sulfasalazine-induced
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agranulocytosis collected in Sweden were included in the replication. All
patients and controls had been treated with sulfasalazine for inﬂamma-
tory joint disease, inﬂammatory bowel disease, or Sj€ogren’s syndrome.
Patient characteristics were compared between replication cases and con-
trols using Fisher’s exact, chi2 and t-tests.
Power calculation
Given a genome-wide signiﬁcance level of 5 3 1028, an ADR incidence
of 0.14% (9), and using an additive genetic model, our sample size was
powered to detect common genetic variants with effect sizes of clinical
utility.43 For example, with 36 cases and 5,000 controls, we had 80%
power to detect an OR of 4 for variants with a minor allele frequency
(MAF) of 40%, and 80% power to detect OR slightly above 5 for var-
iants with an MAF of 20% (Supplementary Figure S3).
Genome-wide array data and analyses
DNA was extracted from peripheral venous blood. Thirty-three cases
recruited in Sweden and France, and 147 Spanish controls were geno-
typed with the Illumina HumanOmni 2.5M chip (Illumina, San Diego,
CA; Figure 3). The remaining 36 Spanish controls had been genotyped
with the Illumina HumanOmni1-Quad 1M chip. Three cases and 96
controls from Germany were genotyped with the Illumina HumanOm-
niExpress 700K array, as were 4,891 controls from the Swedish Twin
Registry. Genotype calls were generated using the Genome Studio soft-
ware from Illumina and the Genome Reference Consortium human
assembly GRCh37.
GWAS quality control (QC) and data management was performed
using PLINK v. 1.9. The resulting merged data included 596,010 SNPs.
Imputation of genotypes was performed using PhaseIT44 and Impute v.
245 with the 1000 Genomes Project reference set (phase III, v. October
2014). The total number of SNPs after imputation was 9,380,034. All
cases and controls were within the European cluster according to genetic
principal component analysis (PCA) (Supplementary Figures S4, S5).
Due to cases and controls being from different countries of Europe, sen-
sitivity analyses were performed by reanalyzing each top ﬁnding in the
largest group of cases and controls, which was from Sweden. See Supple-
mentary Methods for additional details on QC, PCA, and imputation.
All genome-wide analyses were adjusted for sex and the ﬁrst four prin-
cipal components. SNP effects were modeled only as additive. The con-
ventional genome-wide signiﬁcance threshold P < 5 3 1028 was used
to correct for multiple testing.46 Results are presented as Manhattan
plots. When genome-wide signiﬁcant signals were found, analyses were
performed sequentially by adjusting for each genome-wide signiﬁcant sig-
nal until none were left. Logistic regression was used to estimate univari-
ate and multiple models. Genome-wide statistical analyses was
performed using PLINK v. 1.947,48 and individual SNPs were analyzed
statistically, including LD calculation, using R 3.3.1 and the R packages
rms and genetics (R Foundation for Statistical Computing, Vienna, Aus-
tria). The Q-Q plot is shown in Supplementary Figure S6.
HLA allele imputation and analysis of the discovery cohort
Imputation to ﬁrst and second ﬁeld resolution of 180 classical HLA
alleles, amino acid residues, and individual SNPs was performed on the
nonimputed merged and quality-controlled genome-wide data using the
software SNP2HLA with a reference panel of 5,225 individuals.49 Logis-
tic regression was used to test the association between HLA types and
agranulocytosis. The HLA-wide signiﬁcance level was set to 0.05/
1805 2.8 3 1024. When HLA-wide signiﬁcant signals were found,
analyses were performed sequentially by adjusting for each HLA-wide
signiﬁcant signal until none remained. To avoid confounding by indica-
tion, top HLA signals were tested using a cohort of cases and controls
matched for sulfasalazine treatment and/or inﬂammatory joint or bowel
disease that was available from Sweden.
HLA sequencing of the replication cohort
For the replication cohort, HLA sequencing of HLA A, B, C, DP, DQ,
and DR was performed on MiSeq (Illumina) as previously described by
Cereb et al.50 The top HLA types were obtained by sequential adjust-
ment for each signiﬁcant HLA type in the discovery cohort. These ﬁve
HLA types were tested for statistical associations, thus correction for ﬁve
multiple tests was performed (P < 0.01).
Analysis of predictive ability
The predictive ability of logistic regression models for selected HLA
analyses was expressed as the C-statistic (equivalent to the area under the
receiver operating characteristic curve), which is a measure of the ability
of the model to discriminate between cases and controls. A C-statistic of
0.5 indicates predictive ability similar to chance (a 50:50 likelihood of
predicting the outcome), while 1 indicates perfect discrimination. The
number needed to genotype (NNG) to avoid one case was estimated
from the reciprocal of the predicted absolute risk reduction, where the
absolute risk reduction is calculated as the prevalence (adverse drug reac-
tion in the population) 3 the sensitivity of the diagnostic test.
SUPPLEMENTARY MATERIAL is linked to the online version of the arti-
cle at http://www.cpt-journal.com
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